Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Thiamazole
Dechra Regulatory B.V.
QH03BB02
Thiamazole
5 mg/tablet
Coated tablet
POM: Prescription Only Medicine as defined in relevant national legislation
thiamazole
Authorised
2008-11-28
Health Products Regulatory Authority 15 January 2022 CRN00CCR5 Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Felimazole 5 mg Coated Tablets for Cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: ACTIVE SUBSTANCE Thiamazole 5 mg EXCIPIENTS Titanium Dioxide (E171) 0.495 mg Beta-Carotene (E160a) 0.16 mg For a full list of excipeints, see section 6.1. 3 PHARMACEUTICAL FORM Coated tablet. Orange sugar-coated biconvex tablets 5.5 mm diameter. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cats. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the stabilisation of hyperthyroidism in cats prior to surgical thyroidectomy. For the long-term treatment of feline hyperthyroidism. 4.3 CONTRAINDICATIONS Do not use in cats suffering from systemic disease such as primary liver disease or diabetes mellitus. Do not use in cats showing signs of autoimmune disease. Do not use in animals with disorders of white blood cells, such as neutropenia and lymphopenia. Do not use in animals with platelet disorders and coagulopathies (particularly thrombocytopenia). Do not use in pregnant or lactating females. Do not use in cats with hypersensitivity to thiamazole or the excipient, polyethylene glycol. Please refer to section 4.7. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES As thiamazole can cause haemoconcentration, cats should always have access to drinking water. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS If more than 10 mg per day is required animals should be monitored particularly carefully. Use of the product in cats with renal dysfunction should be subject to careful risk : benefit assessment by the clinician. Due to the effect thiamazole can have on reducing the glomerular filtration rate, the effect of therapy on renal function should be monitored closely as deterioration of an underlying condition may occur. Health Products Regulatory Authority 15 January 2022 CRN00CCR5 Page 2 of 5 Haematology must be monitored due to risk of leucopenia o Read the complete document